Function of interleukin-17 and -35 in the blood of patients with hepatitis B-related liver cirrhosis

MIN SHI*, JUE WEI*, JINBIN DONG, WENYING MENG, JIALI MA, TING WANG, NA WANG and YUGANG WANG

Department of Gastroenterology, Shanghai Changning Central Hospital, Shanghai 200336, P.R. China

Received December 15, 2013; Accepted September 18, 2014

DOI: 10.3892/mmr.2014.2681

Abstract. Intrahepatic T helper (Th)17 cytokine and serum interleukin (IL)-17 levels in patients with hepatitis B are positively correlated with the progression of liver cirrhosis (LC). IL-35 can significantly inhibit the differentiation of Th17 cells and the synthesis of IL-17. The present study aimed to investigate the function and expression of IL-17 and IL-35 in the blood of patients with hepatitis B-related LC. The levels of IL-17 and IL-35 in the peripheral blood of 30 patients with chronic hepatitis B (CHB), 79 with LC, 14 with chronic severe hepatitis B (CSHB), and 20 normal controls were detected by ELISA. Quantitative polymerase chain reaction was used to evaluate Epstein-Barr virus-induced gene 3 (EBI3), forkhead box (FOX)P3 and IL-17 mRNA expression levels in peripheral blood mononuclear cells (PBMCs). Western blotting was used to determine protein expression. The liver function of patients and normal controls was measured. EBI3, IL-17 and FOXP3 mRNA expression levels in PBMCs from patients with LC, CHB and CSHB were higher than those in cells from the controls. IL-17 mRNA levels differed significantly according to the Child-Pugh classification and exhibited an upward trend over time in contrast to a downward trend for EBI3 and FOXP3 mRNA. The changes in protein expression in the peripheral blood were consistent with the changes in mRNA expression. Serum IL-17 levels were positively correlated with total bilirubin (TBIL), alanine aminotransferase (ALT) and Child-Pugh grade, and were negatively correlated with albumin. These observed differences were significant. Serum IL-35 levels were negatively correlated with albumin, but not with Child-Pugh grade, ALT and TBIL. IL-17 and IL-35 may be critically involved in the pathogenesis of hepatitis B-related LC.

Introduction

Hepatitis B virus (HBV) infection remains a global public health problem. More than 350 million people worldwide are suffering from persistent HBV infection (1). Chronic HBV infection is a serious clinical problem due to the potentially adverse sequelae, such as hepatic decompensation and the development of cirrhosis or hepatocellular carcinoma (2). The Child-Pugh classification is the common liver reserve function classification standard of cirrhosis, guides treatment and prognosis, and has very important reference value (3,4). The determination of Child-Pugh score, which may range from 5 to 15, is based on the presence and severity of ascites and hepatic encephalopathy, the prolongation of prothrombin time, and the levels of serum bilirubin and albumin. According to their Child-Pugh scores, patients are classified into three classes; A, B and C, with Child-Pugh scores 5-6, 7-9 and 10-15, respectively (5). The complication rate of chronic HBV is associated with the degree of viral replication, inflammation and fibrosis (6,7,8).

Cytokines are important chemical mediators synthesized and secreted from immune cells, which act on their corresponding receptors and regulate immune cell differentiation and proliferation, thus coordinating the immune and inflammatory responses and progression of fibrosis. In previous years, studies have demonstrated that intrahepatic T helper (Th)17 cytokines and serum interleukin (IL)-17 levels in patients with hepatitis B are positively correlated with the progression of liver cirrhosis (LC) (1,9). Cytokines do not act in isolation and are synthesized and secreted through mutual adjustment. They can regulate receptor expression and influence the biological effects of the cytokine network to achieve synergistic, antagonistic or functional expansion. IL-35 can significantly inhibit the differentiation of Th17 cells in addition to the synthesis of IL-17 (10). Thus far, few studies have investigated IL-17 and IL-35 in patients with LC. In the current study, the expression levels of IL-17 and -35 in the blood of patients with hepatitis B-related LC was investigated.

Patients and methods

Study objective. The present study included out- or inpatients treated at the Department of Gastroenterology and Infectious Diseases (Changning District Central Hospital, Shanghai,
Table I. Clinical characteristics of patients.

| Clinical feature | NC  | A   | B  | C   | CHB | CSHB |
|------------------|-----|-----|----|-----|-----|------|
| Case (n)         | 20  | 27  | 30 | 22  | 30  | 14   |
| Gender           |     |     |    |     |     |      |
| Male (n)         | 12  | 21  | 25 | 19  | 22  | 12   |
| Female (n)       | 8   | 6   | 5  | 3   | 8   | 2    |
| Age (years)†     | 39.5±9.0 | 45.4±7.2 | 52.9±8.9 | 56.9±9.8 | 38.1±6.7 | 47.0±8.2 |

†Data are presented as the mean ± standard deviation. NC, normal control; CHB, chronic hepatitis B; CSHB, chronic severe hepatitis B.

Materials and reagents. The FTC-3000 quantitative polymerase chain reaction (qPCR) instrument was obtained from Funglyn Biotech, Inc. (Scarborough, ON, Canada); the SYBR Green Real-Time PCR Master Mix was from Toyobo Co. (Osaka, Japan); primers for L-35 (Epstein-Barr virus-induced gene 3; EBI3), IL-17 and forkhead box P3 (FOXP3) were designed by the authors and synthesized by GeneRay Biotech Co., Ltd (Shanghai, China) (Table II); rabbit anti-IL-17 polyclonal antibodies were from Abcam (Cambridge, MA, USA); mouse anti-β-actin monoclonal antibodies were from Cell Signaling Technology, Inc. (Danvers, MA, USA); mouse anti-β-actin monoclonal antibodies, goat anti-rabbit immunoglobulin G (IgG) (whole molecule)-peroxidase antibodies and goat anti-mouse IgG (Fc specific)-peroxidase antibodies were from Sigma-Aldrich (St. Louis, MO, USA); the Bicinchoninic Acid (BCA) Protein Assay kit was from Thermo Fisher Scientific (Rockford, IL, USA); the Amersham ECL plus Western Blotting Detection System was from GE Healthcare Bio-Sciences (Pittsburgh, PA, USA); and the ELISA kit was from Uscn Life Science, Inc. (Wuhan, China).

Isolation, cryopreservation and resuscitation of peripheral blood mononuclear cells (PBMCs). Fresh blood (5 ml) was collected prior to surgery and at follow-up (1, 4 and 6 months), put into an EDTA anticoagulant tube, and sent to the laboratory within 2 h. The samples were centrifuged at 1,500 x g for 5 min to obtain the plasma, which was stored at -70°C. The remaining cell pellets were mixed with 3 ml phosphate-buffered saline (PBS) solution, added slowly to 3 ml prepared ficoll lymphocyte separation medium along the pipette wall and transferred to a horizontal rotor at 800 x g for 15 min. PBMCs in the intermediate layer were removed and added to a Falcon tube containing 3 ml PBS solution. The cells were washed at 200 x g for 10 min, added to 5 ml PBS solution following supernatant removal, washed once at 200 x g for 10 min, counted under a fluorescent microscope (Olympus IX51; Olympus, Tokyo, Japan) and then stored subsequent to supernatant removal. The cells in the three tubes were frozen with 500 µl RPMI-1640 medium containing 10% dimethyl sulfoxide and 10% fetal bovine serum, placed in a -80°C freezer overnight and transferred to liquid nitrogen for storage on the next day.

qPCR. Total RNA was extracted by TRizol® reagent, and detected with ultraviolet spectrophotometry to determine RNA purity and concentration. Total RNA (2 µg) was reverse transcribed into cDNA. qPCR was performed with the ReverFra Ace qPCR RT kit (Toyobo Co.). Reverse transcription (RT) products were amplified for β-actin, IL-35 (EBI3), FOXP3 and IL-17 genes. The mRNA expression and gradient of each group were compared with a fully automated gel imaging analysis system (Gel Doc 2000; Bio-Rad, Hercules, CA, USA), subsequent to the amplified products undergoing gel electrophoresis. All results were corrected with reference to β-actin. The sequences and fragment lengths of the PCR primers are illustrated in Table II. qPCR was conducted under the following conditions: 40 cycles including initial denaturation at 94°C for 30 sec, denaturation at 94°C for 20 sec, annealing at 61°C for 30 sec, extension at 72°C for 30 sec and a final extension at 72°C for 1 min followed by termination at 4°C.

Western blotting. PBMCs were added to sodium dodecyl sulfate (SDS) lysis solution (100-400 µl; mainly containing...
50 mM Tris (pH 8.1), 1% SDS and inhibitors including sodium pyrophosphate, β-glycerophosphate, sodium orthovanadate, sodium fluoride, EDTA and leupeptin. Cells were subjected to high-speed homogenization with ice for 1 min, ultrasonic cracking three times within 20 sec, and centrifugation at 12,000 x g at 4˚C for 20 min. The supernatant following centrifugation was transferred to a 0.5-ml centrifuge tube and stored at -80˚C. The BCA protein assay method was used for the SDS-PAGE, transmembrane, immune response, development and gel image analysis of EBI3, FOXP3 and IL-17.

Statistical analysis. SPSS version 13.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis and the values were expressed as the mean ± standard deviation. Numerical data were analyzed by the χ² test, and quantitative differences between groups were processed by analysis of variance. Pair-wise comparisons were performed by the q test. The cumulative varicose vein rebleeding and survival rates were analyzed by a product-limit method (Kaplan-Meier) and all statistical tests were bilateral probability tests (α=0.05). P<0.05 was considered to indicate a statistically significant difference.

Results

Quantitative determination of EBI3, IL-17 and FOXP3 expression by qPCR. The results of reverse transcription qPCR (RT-qPCR) are presented in Fig. 1. EBI3, IL-17 and FOXP3 mRNA expression levels in PBMCs from patients with LC, CHB and CSHB were significantly higher than those in the controls (P<0.01 or P<0.05). The levels of IL-17, EBI3 and FOXP3 mRNA differed significantly according to the Child-Pugh classification A vs. B vs. C.

Table II. Sequences for reverse transcription quantitative polymerase chain reaction.

| mRNA           | Sequence (5'-3')         | Amplicon size (bp) |
|----------------|--------------------------|---------------------|
| IL-35 (EBI3)   | F: TCATTGCCACGTACAGGCTC  | 208                 |
|                | R: GGGTGGGGCTTGTAGTGTG   |                     |
| IL-17          | F: AGATTACTACAACCGATCCCT | 151                 |
|                | R: GGGGACAGAGTTCATGTGTA  |                     |
| Forkhead box P3| F: GTGGCCCCGATGTAGAAG    | 238                 |
|                | R: GGAGCCCTGTGGGATATG    |                     |
| β-actin        | F: TGGAGAAAATCTGGCACCA   | 189                 |
|                | R: CAGGCCTACAGGGATAGCAC  |                     |

IL, interleukin; EBI3, Epstein-Barr virus-induced gene 3; F, forward; R, reverse.
SHI et al: EFFECT OF HEPATITIS B-RELATED LIVER CIRRHOSIS ON IL-35/IL-17 EXPRESSION

Table III. Correlations between liver function and serum concentrations of IL-17 and IL-35.

|                | IL-17 |         | IL-35 |         |
|----------------|-------|---------|-------|---------|
|                | \(r\) | \(P\)   |     \(r\) | \(P\)   |
| Total bilirubin| 0.338 | <0.001  | 0.122 | 0.146   |
| Albumin        | -0.698| <0.001  | -0.384| <0.001  |
| Alanine aminotransferase | 0.248 | 0.003  | 0.038 | 0.651   |
| Child-Pugh classification | 0.873 | <0.001 | -0.798| <0.001  |

IL, interleukin.

Figure 2. Changes in expression of IL-35 (Epstein-Barr virus-induced gene 3), IL-17 and FOXP3 by western blotting. Lanes: 1, normal control; 2, LC Child-Pugh class A; 3, LC Child-Pugh class B; 4, LC Child-Pugh class C; 5, chronic hepatitis B; 6, chronic severe hepatitis B. IL, interleukin; FOXP3, forkhead box P3; LC, liver cirrhosis.

Figure 3. ELISA determination of IL-17 and IL-35 serum concentration. Serum concentrations of (A) IL-17 and (B) IL-35. IL, interleukin; NC, normal control; LC-A, liver cirrhosis Child-Pugh class A; LC-B, LC Child-Pugh class B; LC-C, LC Child-Pugh class C; CHB, chronic hepatitis B; CSHB, chronic severe hepatitis B.

exhibited the highest expression; Child-Pugh C vs. A, \(P<0.001\); Child-Pugh C vs. B, \(P=0.373\); Child-Pugh B vs. A, \(P<0.001\).

Expression levels of EBI3, IL-17 and FOXP3 mRNA in patients with LC were significantly higher than in the CHB group (EBI3, Child-Pugh C/B/A vs. CHB, \(P<0.001\) for all three comparisons; IL-17, Child-Pugh C/B/A vs. CHB, \(P<0.001\) for all three comparisons; FOXP3, Child-Pugh C vs. CHB, \(P=0.001\); Child-Pugh B vs. CHB, \(P=0.003\); Child-Pugh A vs. CHB, \(P<0.001\)). There was also a significant difference in EBI3, IL-17 and FOXP3 mRNA expression between the different Child-Pugh classes compared with CSHB. For EBI3: Child-Pugh C vs. CSHB, \(P=0.820\); Child-Pugh B vs. CSHB, \(P=0.330\); Child-Pugh A vs. CSHB, \(P=0.003\). For IL-17: Child-Pugh C vs. CSHB, \(P<0.001\); Child-Pugh B vs. CSHB, \(P=0.966\); Child-Pugh A vs. CSHB, \(P<0.001\). For FOXP3: Child-Pugh C vs. CSHB, \(P=0.015\);
Child-Pugh B vs. CSHB, \( P=0.003 \); Child-Pugh A vs. CSHB, \( P=0.010 \).

**Determination of IL-35 (EBI3), FOXP3 and IL-17 expression levels with western blotting.** Western blotting indicated that in patients with LC, CHB and CSHB, IL-35 (EBI3), FOXP3 and IL-17 protein expression levels were significantly higher than those in the NC group. Patients with LC with different Child-Pugh classes also demonstrated differences in EBI3, FOXP3 and IL-17 protein expression levels (EBI3, Child-Pugh A had relatively high expression; IL-17, Child-Pugh C had relatively high expression; and FOXP3, Child-Pugh A had relatively high expression). The change in protein expression was consistent with that observed in the mRNA expression (Fig. 2).

**Correlation analysis.** Serum alanine aminotransferase (ALT), total bilirubin (TBIL) and albumin levels were compared with IL-17 and IL-35 levels. Correlation analysis identified that serum IL-17 and IL-35 levels were negatively correlated with albumin and serum IL-17 levels were significantly positively correlated with TBIL, ALT and Child-Pugh class (\( P<0.01 \)). The serum IL-35 levels were negatively correlated with Child-Pugh class and demonstrated no correlation with ALT and TBIL (Table III).

**Discussion**

IL-17 is predominantly produced by activated Th17 cells, and the serum IL-17 level reflects the number and function of Th17 cells to a certain extent (13-15). A study by Sun et al (16) suggested that the increase in Th17 cells in patients with LC promotes hepatic stellate cell activity, which leads to further disease progression. Ye et al (17) indicated that the number of IL-17-positive cells increases with stage of liver fibrosis. This may be associated with the crucial function that transforming growth factor (TGF)-\( \beta \)1 has in the development of liver fibrosis and the fact that cooperation between TGF-\( \beta \)1 and IL-6 may promote maturation of CD4\(^+\) T cells into Th17 cells (18-20). Th17 cells produce IL-6 and IL-17, which promote chronic liver inflammation, leading to the occurrence of cirrhosis. The current study identified that EBI3, IL-17 and FOXP3 mRNA and protein expression levels in PBMCs from patients with LC, CHB and CSHB were higher than those in the controls. Serum concentrations of IL-17 rose significantly, which were negatively correlated with albumin, but positively correlated with TBIL, ALT and Child-Pugh class. Serum IL-17 levels increased with LC Child-Pugh classification and were correlated with liver inflammation, necrosis and synthesis function, suggesting an important function in the occurrence and development of liver fibrosis.

IL-35 is a heterodimer that consists of the EBI3 protein and IL-12 p35 subunit (10, 21, 22). IL-35 is secreted mainly by T regulatory (Treg) cells. Its primary physiological function may be to induce the formation of Th1 cells and facilitate the proliferation of Treg cells (23). A previous study (10) established that IL-35 can inhibit differentiation of Th17 cells and IL-17 production and that IL-17 production is greater in spleen cells from EBI3-deficient mice. Liu et al (24) have demonstrated that EBI3 inhibits the responses of Th17, Th1, IL-2 and Treg. TGF-\( \beta \) can enhance the proinflammatory response by accelerating Th17 differentiation. IL-35 may upregulate interferon-\( \gamma \), which can prevent phosphorylation of the TGF-\( \beta \) receptor downstream effector SMAD family member 3. This blocks TGF-\( \beta \) binding to its receptor and prevents the differentiation of Th17 cells (15). Retinoid-related orphan receptor \( \gamma \)t (ROR\( \gamma \)t) is an important transcription factor of Th17 cell differentiation, and EBI3 deletion increased the expression of IL-17, IL-22 and ROR\( \gamma \)t (25). Several research groups have demonstrated that specific expression of FOXP3 in Treg cells is required for the Treg cell development and function (26-28).

The current study identified that patients with CHB, LC and CSHB, IL-17, IL-35 and FOXP3 mRNA and protein expression levels were higher than those in the NC group. Serum levels of IL-35 were significantly increased, which indicated that proinflammatory cytokines were increased in the cirrhotic process, while anti-inflammatory cytokine IL-35 levels were correspondingly upregulated. IL-17 mRNA and protein levels increased with LC Child-Pugh classification, whereas the expression of IL-35 mRNA and protein was reduced. The downregulated EBI3 content was also reduced following transcription into the EBI3 subunit and binding with the p35 subunit to form IL-35. Serum concentrations and protein expression levels are consistent with the mRNA. Further analysis demonstrated that serum IL-35 levels were negatively correlated with the LC Child-Pugh classification. The results indicate that in LC, reduced IL-35 expression hinders Treg cell amplification from secreting more IL-35. Thus, IL-35 cannot inhibit Th17 cell differentiation and IL-17 overexpression, excessive inflammation reactions are not prevented and the development of LC is promoted. The mRNA and protein levels of FOXP3 support this conclusion.

Previous studies have suggested that immune hyper-reactivity has an important function in the pathogenesis of severe hepatitis (29). It has been demonstrated that in patients with CHB, LC and CSHB, mRNA and protein levels of IL-17, IL-35 and FOXP3 are higher than those in the NC group,
and the serum levels of IL-17 and IL-35 are significantly increased. Treg cells can suppress the immune response from over-reaction and reduce the immunopathological damage, however, they also inhibit the cytotoxic response against pathogens, which may lead to the exacerbation of infection.

The preliminary view is that IL-17 and IL-35 may be critically involved in the pathogenesis of hepatitis B-related LC. Studies on the association between IL-17 and IL-35 may further the understanding of the immune mechanisms involved in the progression of LC, and aid the development novel therapeutic targets. The present study had only a small number of cases and short follow-up; therefore, it was not possible to evaluate the dynamic changes in IL-17 and IL-35. Further studies with a larger number of samples and extended follow-up are warranted.

Acknowledgements

This study was funded by a grant from the Shanghai Municipal Health Bureau Shanghai Municipal Health Bureau Key Disciplines (no. ZK2012A05).

References

1. Wang L, Chen S and Xu K: IL-17 expression is correlated with hepatitis B-related liver diseases and fibrosis. Int J Mol Med 27: 385-392, 2011.
2. Liaw YF and Chu CM: Hepatitis B virus infection. Lancet 373: 582-592, 2009.
3. Cholongitas E, Papatheodoridis GV, Vangeli M, et al: Systematic review: The model for end-stage liver disease - should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther 22: 1079-1089, 2005.
4. Infante-Rivard C, Esnaola S and Villeneuve JP: Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 7: 660-664,1987.
5. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC and Williams R: Transsection of the oesophagus for bleeding oesophageal varices. Br J Surg 60: 646-649, 1973.
6. Lok AS and McMahon B: Chronic hepatitis B. Hepatology 45: 507-539, 2007.
7. Iloeje UH, Yang HI, Su J, et al: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130: 678-686, 2006.
8. Kao JH: Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 1: 415-430, 2007.
9. Zhang P, Chen Z, Gong Z, et al: Study on relationship between Th17 cells, Th17 cytokine and the inflammatory activity of liver tissue in post hepatitis B cirrhosis. Wei Chang Bing Xue 15: 456-461, 2010 (In Chinese).
10. Niedbala W, Wei XQ, Cai B, et al: IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37: 3021-3029, 2007.
11. Chinese Society of Hepatology, Chinese Society of Infectious Diseases and Chinese Medical Association: Viral hepatitis prevention and treatment programs. Zhonghua Gan Zhe Zhi 8: 324-329, 2000 (In Chinese).
12. Chinese Society of Hepatology, Chinese Society of Infectious Diseases and Chinese Medical Association: The guideline of prevention and treatment for chronic hepatitis B. Zhonghua Gan Zhe Zhi 13: 881-891, 2005 (In Chinese).
13. Harrington LE, Hatton RD, Mangan PR, et al: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132, 2005.
14. Infante-Duarte C, Horton HF, Byrne MC and Kamradt T: Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 165: 6107-6115, 2000.
15. Park H, Li Z, Yang X0, et al: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141, 2005.
16. Sun HQ, Zhang JY, Zhang H, Zou ZS, Wang FS and Jia JH: Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis. J Viral Hepat 19: 396-403, 2012.
17. Ye Y, Xie X, Yu J, et al: Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol 30: 546-555, 2010.
18. Mangan PR, Harrington LE, O'Quinn DB, et al: Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231-234, 2006.
19. Bettelli E, Carrier Y, Gao W, et al: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 255-238, 2006.
20. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM and Stockinger B: TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189, 2006.
21. Olson BM, Sullivan JA and Burlingham WJ: Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol 4: 315, 2013.
22. Vignali DA and Kuchroo VK: IL-12 family cytokines: immunologically competent cells. Nat Immunol 13: 722-728, 2012.
23. Collison LW, Chaturvedi V, Henderson AL, et al: IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11: 1093-1101, 2010.
24. Liu JQ, Liu Z, Zhang X, et al: Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. J Immunol 188: 3099-3106, 2012.
25. Yang J, Yang M, Huo TM, et al: Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORgamma in human CD4+ T cells. J Immunol 188: 3099-3106, 2012.
26. Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development of regulatory T cells. Nature 441: 386-391, 2006.
27. Kuchroo VK, Wherry EJ, Lanzavecchia A, et al: IL-12 family cytokines and their role in the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 315, 2003.
28. Bettelli E, Chozas M, Raulet HD, et al: TGF-beta differentially regulates the development of Th17 and regulatory T cells. J Immunol 183: 3265-3272, 2009.
29. Bettelli E, Gause WC, Kuchroo VK: CD4+ effector T cell differentiation. Nat Rev Immunol 7: 792-805, 2007.
30. Betz S, Sun J, Yang L, et al: The cytokine profile of CD4+CD25+ regulatory T cells. J Immunol 176: 1022-1030, 2006.
31. Kuchroo VK, Berzofsky JA, Davis MM: The role of regulatory T cells in self-tolerance and autoimmunity. Nat Rev Immunol 5: 157-166, 2005.